| |
To all,
I am an anesthesiologist but was also an internal medicine resident and had to deal with diabetics every frigging day.
I saw a mention of CYGN on Pointcast today and came to this thread.
If CYGN gets FDA approval, obviously it will be a tremendous positive for the stock. As to the sciences behind the GlucoWatch, it all seems plausible but not being a research type, I have no idea whether it will work reliably or not (does it work on sweaty skin or on humid days or does it work reliably on the same patch of skin repeatedly, etc.)
I know of only one other company working on a similar product, which actually works on a photometric principle (like pulse oximetry), not on an electrochemical principle like the GlucoWatch. The company, whose name escapes me for now, is based in western PA. It was a BB stock. I stopped following it more than two years ago.
In terms of TA, the jump in volume today was obviously very reassuring, and the price barely moved up, giving me a chance to get in tomorrow, but this is nonetheless a speculative stock at this point. This reminds me of Duramed Pharmaceuticals (DRMD), which was essentially a speculative stock until they got their FDA approval a couple months ago...
H. Jung, M.D. |
|
